We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Thermo Fisher Scientific Inc | NYSE:TMO | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 4.10 | 0.69% | 594.80 | 597.18 | 586.65 | 591.16 | 1,040,939 | 22:35:43 |
From May 2019 to May 2024
By Maria Armental
Thermo Fisher Scientific Inc. will buy Affymetrix Inc. in a roughly $1.3 billion cash deal that would boost its biogenetic analysis portfolio, the company said Friday.
Under the terms of the deal, which requires approval by Affymetrix shareholders, Thermo Fisher is to pay $14 a share in cash. Affymetrix's shares closed Friday at $9.21.
Thermo Fisher said the deal, which it expects to close by the end of the second quarter, would add 10 cents a share to adjusted profit in the first full year of ownership and result in about $70 million in savings by year three.
Santa Clara, Calif.-based Affymetrix, which carried an accumulated loss of about $500 million as of Sept. 30, has about $350 million in annual revenue, while Waltham, Mass.-based Thermo Fisher has about $17 billion in annual revenue, according to regulatory filings.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
January 08, 2016 18:43 ET (23:43 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Thermo Fisher Scientific Chart |
1 Month Thermo Fisher Scientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
